RATIONALE: Recent studies of inhaled tobramycin in subjects with cystic fibrosis (CF) find less clinical improvement than previously observed. Nonhuman data suggest that in some strains of Pseudomonas aeruginosa, azithromycin can antagonize tobramycin. OBJECTIVES: We tested the hypothesis that concomitant azithromycin use correlates with less improvement in key outcome measures in subjects receiving inhaled tobramycin while not affecting those receiving a comparative, nonaminoglycoside inhaled antibiotic. METHODS: We studied a cohort of 263 subjects with CF enrolled in a recent clinical trial comparing inhaled tobramycin with aztreonam lysine. We performed a secondary analysis to examine key clinical and microbiologic outcomes based on concomitant, chronic azithromycin use at enrollment. MEASUREMENTS AND MAIN RESULTS: The cohort randomized to inhaled tobramycin and reporting azithromycin use showed a significant decrease in the percent predicted FEV1 after one and three courses of inhaled tobramycin when compared with those not reporting azithromycin use (28 d: -0.51 vs. 3.43%, P < 0.01; 140 d: -1.87 vs. 6.07%, P < 0.01). Combined azithromycin and inhaled tobramycin use was also associated with earlier need for additional antibiotics, lesser improvement in disease-related quality of life, and a trend toward less reduction in sputum P. aeruginosa density. Subjects randomized to inhaled aztreonam lysine had significantly greater improvement in these outcome measures, which were unaffected by concomitant azithromycin use. Outcomes in those not using azithromycin who received inhaled tobramycin were not significantly different from subjects receiving aztreonam lysine. Azithromycin also antagonized tobramycin but not aztreonam lysine in 40% of P. aeruginosa clinical isolates tested in vitro. CONCLUSIONS: Oral azithromycin may antagonize the therapeutic benefits of inhaled tobramycin in subjects with CF with P. aeruginosa airway infection.
RATIONALE: Recent studies of inhaled tobramycin in subjects with cystic fibrosis (CF) find less clinical improvement than previously observed. Nonhuman data suggest that in some strains of Pseudomonas aeruginosa, azithromycin can antagonize tobramycin. OBJECTIVES: We tested the hypothesis that concomitant azithromycin use correlates with less improvement in key outcome measures in subjects receiving inhaled tobramycin while not affecting those receiving a comparative, nonaminoglycoside inhaled antibiotic. METHODS: We studied a cohort of 263 subjects with CF enrolled in a recent clinical trial comparing inhaled tobramycin with aztreonam lysine. We performed a secondary analysis to examine key clinical and microbiologic outcomes based on concomitant, chronic azithromycin use at enrollment. MEASUREMENTS AND MAIN RESULTS: The cohort randomized to inhaled tobramycin and reporting azithromycin use showed a significant decrease in the percent predicted FEV1 after one and three courses of inhaled tobramycin when compared with those not reporting azithromycin use (28 d: -0.51 vs. 3.43%, P < 0.01; 140 d: -1.87 vs. 6.07%, P < 0.01). Combined azithromycin and inhaled tobramycin use was also associated with earlier need for additional antibiotics, lesser improvement in disease-related quality of life, and a trend toward less reduction in sputum P. aeruginosa density. Subjects randomized to inhaled aztreonam lysine had significantly greater improvement in these outcome measures, which were unaffected by concomitant azithromycin use. Outcomes in those not using azithromycin who received inhaled tobramycin were not significantly different from subjects receiving aztreonam lysine. Azithromycin also antagonized tobramycin but not aztreonam lysine in 40% of P. aeruginosa clinical isolates tested in vitro. CONCLUSIONS: Oral azithromycin may antagonize the therapeutic benefits of inhaled tobramycin in subjects with CF with P. aeruginosa airway infection.
Authors: Michael W Konstan; Patrick A Flume; Matthias Kappler; Raphaël Chiron; Mark Higgins; Florian Brockhaus; Jie Zhang; Gerhild Angyalosi; Ellie He; David E Geller Journal: J Cyst Fibros Date: 2010-11-12 Impact factor: 5.482
Authors: Felix Ratjen; Lisa Saiman; Nicole Mayer-Hamblett; Larry C Lands; Margaret Kloster; Valeria Thompson; Peggy Emmett; Bruce Marshall; Frank Accurso; Scott Sagel; Michael Anstead Journal: Chest Date: 2012-11 Impact factor: 9.410
Authors: D Macdonald; L Cuthbertson; C Doherty; S Campana; N Ravenni; G Taccetti; J R W Govan Journal: J Antimicrob Chemother Date: 2010-09-13 Impact factor: 5.790
Authors: David P Nichols; Silvia Caceres; Lindsay Caverly; Cori Fratelli; Sun Ho Kim; Ken Malcolm; Katie R Poch; Milene Saavedra; George Solomon; Jennifer Taylor-Cousar; Samuel Moskowitz; Jerry A Nick Journal: J Surg Res Date: 2013-02-24 Impact factor: 2.192
Authors: Baroukh M Assael; Tacjana Pressler; Diana Bilton; Michael Fayon; Rainald Fischer; Raphael Chiron; Mario LaRosa; Christiane Knoop; Noel McElvaney; Sandra A Lewis; Mark Bresnik; A Bruce Montgomery; Christopher M Oermann Journal: J Cyst Fibros Date: 2012-09-15 Impact factor: 5.482
Authors: A J Lopes; T T Mafort; A de Sá Ferreira; M C Santos de Castro; M Cássia de Firmida; E de Andrade Marques Journal: Monaldi Arch Chest Dis Date: 2012 Sep-Dec
Authors: John J Brewington; Jessica Backstrom; Amanda Feldman; Elizabeth L Kramer; Jessica D Moncivaiz; Alicia J Ostmann; Xiaoting Zhu; L Jason Lu; John P Clancy Journal: JCI Insight Date: 2018-02-22
Authors: Silvia M Caceres; Kenneth C Malcolm; Jennifer L Taylor-Cousar; David P Nichols; Milene T Saavedra; Donna L Bratton; Samuel M Moskowitz; Jane L Burns; Jerry A Nick Journal: Antimicrob Agents Chemother Date: 2014-09-02 Impact factor: 5.191
Authors: Martina Koeva; Alina D Gutu; Wesley Hebert; Jeffrey D Wager; Lael M Yonker; George A O'Toole; Frederick M Ausubel; Samuel M Moskowitz; Diane Joseph-McCarthy Journal: Antimicrob Agents Chemother Date: 2017-11-22 Impact factor: 5.191
Authors: Dave P Nichols; Carrie L Happoldt; Preston E Bratcher; Silvia M Caceres; James F Chmiel; Kenneth C Malcolm; Milene T Saavedra; Lisa Saiman; Jennifer L Taylor-Cousar; Jerry A Nick Journal: J Cyst Fibros Date: 2016-12-24 Impact factor: 5.482
Authors: Edith T Zemanick; Thida Ong; Cori L Daines; Elisabeth P Dellon; Marianne S Muhlebach; Charles R Esther Journal: Pediatr Pulmonol Date: 2016-04-13
Authors: Ranjani Somayaji; Renee Russell; Jonathan D Cogen; Cristopher H Goss; Sarah E Nick; Milene T Saavedra; Jennifer L Taylor-Cousar; Jerry A Nick; Dave P Nichols Journal: Ann Am Thorac Soc Date: 2019-07
Authors: Jonathan D Cogen; Anna V Faino; Frankline Onchiri; Ronald L Gibson; Lucas R Hoffman; Matthew P Kronman; Margaret Rosenfeld; David P Nichols Journal: Ann Am Thorac Soc Date: 2021-02